PR Newswire

The Bulletin

Times Advertising

.

BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate

Written by PR Newswire

BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate

BioDlink congratulates Junshi Biosciences on receiving IND approval from China'sNMPA for JS212, the company's first bispecific ADC.
JS212 combines dual-targeting antibody technology with a cytotoxic payload, representing a next-generation therapeutic.
BioDlink provided end-to-end development and manufacturing support, showcasing its industry-leading...

Simple Home Upgrades That Improve Security, Comfort and Everyday Living

What is a Design and Build Contract? A Complete Guide

How Melbourne Homeowners Keep Their Homes Clean Year-Round (Without Spending Their Weekends Doing It)

Why Choosing The Right GP Bundoora Is Key To Long-Term Health Management

Why BMW Used Cars Are A Smart Choice For Modern Drivers

SMSF Loan Experts Guiding Smarter Property Investment Through Super

Why Professional Cleaning Services Are Essential For Commercial Workspaces

From Purchase to Protection: What Happens After You Buy a Home

The Essential Guide to Pool Water Testing: Why It Matters and How to Do It Right

Why Shutter Blinds Are a Practical Window Solution for Modern Interiors

Understanding Wisdom Teeth Extraction And Why It Is Sometimes Necessary

Common Mental Health Challenges Faced by Teenagers Today